The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
HOME > REGULATORY
REGULATORY
- Partial Change in Approval Is Not Necessary for 14 Products Including Allegra: PFSB
October 4, 2011
- Bill for Healthcare Reform for Elderly to Be Submitted to 2012 Diet: Health Minister
October 4, 2011
- METI Budget Request Includes ¥3.3 Bil. to Promote “Healthcare Industry Creation”
October 3, 2011
- Mr Akagawa of ELD Stresses Need for Closer East Asian Cooperation to Promote Multinational Trials
October 3, 2011
- Health Insurance Committee Unable to Agree on Proposed Fixed-sum Examination Fee
October 3, 2011
- Obama Administration’s Deficit-reduction Plan Calls For Shorter Exclusivity Period for Biologics
October 3, 2011
- Nat’l Medical Expenditure Rose 3.4% to Record ¥36,006.7 Billion in FY2009: MHLW
September 30, 2011
- MHLW Drug Subcommittee Withholds Approval of Additional Indication for Epogin
September 30, 2011
- MHLW to Request Perpetuation of “Add-on Credits,” “Credits for High-level R&D Investment”
September 29, 2011
- MHLW to Request Budget of ¥29,588.2 Bil., Special Framework Budget of ¥105.9 Bil. for FY2012
September 29, 2011
- CSIMC’s Committee to Assess Premium for New Drug Development Based on Results of Market Price Survey
September 29, 2011
- Record Number of New AIDS Cases Reported in 2nd Qtr. of 2011
September 28, 2011
- MHLW Approves 18 New Products
September 27, 2011
- MHLW Asks Prefectural Authorities for Cooperation to Ensure Stable Supply of Flu Vaccine
September 27, 2011
- MHLW Announces JAN for 8 Drug Candidates
September 26, 2011
- Korosho Plans to Apply for PIC/S Membership in Early 2012
September 26, 2011
- Daiichi Sankyo Announces Approval of Silodosin in China; Aims for Launch in 2012
September 26, 2011
- Growth in Prescriptions of Prazaxa May Hit Snag Due to “Blue Letter”
September 26, 2011
- Why Generics’ Market Share Appears So Low in Japan; 20% Actually Means 35.7% if Overseas Calculation Method is Used
September 26, 2011
- Prime Minister Noda Stresses Need for Comprehensive Reform in First Major Policy Speech
September 26, 2011
ページ
The pharmaceutical industry is ever-changing. Recruiters must evolve accordingly and prepare well in advance for future talent needs.This means predicting the changes and trends that will impact the market, industry, and your organization, and how this will affect talent requirements.…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…